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CUPROPHANE membranes during haemodialysis signific-
antly increase the plasma levels of CSadesArg (maximal
55/g CSadesArg/1 blood after 30 min) whereas Hemophane
or Polysulphonemembranes induce only low plasma
levels of CSadesArg. CSadesArg generated in vitro by yeast
incubation of autologous plasma stimulates PMN chemo-
taxis and oxidative metabolism but has no effect on en-
zyme release. Preincubation of whole blood with CSadesArg
causes aggregation and changed oxidative burst activity
of the isolated PMN. These changes are similar to those
found in cells from patients after haemodialysis with
cuprophane membranes. So the elevated plasma levels of
C5adesArg after haemodialysis explain some of the changes
in PMN functions, but additional mechanisms have to be
assumed.
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Introduction
During haemodialysis (HD) with various mem-
branes complement components are activated,
which results in elevated levels of C5a and C3a. 1’2
Additionally neutrophil granulocytes (PMN) are
activated, which results in the release of lysosomal
enzymes and an altered oxidative metabolism.4 To
explain the change in the PMN functions two effects
have to be evaluated: a direct effect of the
membrane material on PMN and an indirect effect
of membrane activated plasma components on the
cells. If the two effects are exerted, they may differ
in their extent, in their kinetic, and in their
dependence on the membrane material. They can
be studied in two ways: by using membrane
activated cells without the addition of plasma and
by using normal cells with activated plasma.
In this study we set out to investigate the
incubation of normal PMN with yeast activated
plasma as an in vitro model of the plasma effects
during haemodialysis.
Material and Methods
Isolation of human PMN: Blood was drawn by
venipuncture after obtaining written consent from
normal, healthy donors. PMN were isolated using
Ficoll (Pharmacia-LKB, Bromma, Sweden) separa-
tion and sedimentation of erythrocytes. The cells
represented more than 98% granulocytes with a
viability of about 98% by Trypan exclusion.
Generation of C5adesArg: Autologous plasma was acti-
vated by incubation with baker’s yeast (1 mg m1-1)
for 60 min at 37C. Plasma was inactivated by
incubation for 30 min at 56C.
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Concentration of C5a and C5adesArg was measured
with an ELISA (Behringwerke, Marburg, Ger-
many).
Chemotaxis assay: Chemotactic assays were performed
in modified Boyden chambers. 7 Activated plasma
(2.5-20%) in HBSS (Gibco, Germany) was put in
the lower compartment and the PMN (106) in the
upper compartment of the Boyden chambers.
Cellulose ester filters (ME 29, Schleicher and
Schtill, Dassel, Germany) were used. The chambers
were incubated for 90 min at 37C, then
the filters were removed, stained with hematoxylin,
and mounted on slides. The PMN were counted in
the filters at every 10/m interval by a computerized
imaging method (Bausch and Lomb, Frankfurt,
Germany) and the chemotactic index (CI) calcu-
lated, which reflects the mean distance travelled by
the activated cells. 7
Cytochrome c test: Superoxide anion generation was
measured by cytochrome c reduction. PMN (106)
were incubated with 75/M cytochrome c and
stimuli (Phorbol 12-myristate 13-acetate, PMN,
1 #g m1-1 or activated plasma 0.3-20% as indicated
in results) in Hanks’ balanced salt solution
(HBSS) for 10 min at 37C. The reaction was
stopped by cooling in ice and centrifugation (10
min, 200 x g’). The absorption of the supernatants
was determined at 550nm, and the superoxide
generation was calculated.
Elastase release: PMN (4 x 106) were incubated with
activated plasma (2.5-20% as indicated in results)
in HBSS for 15 min at 37C. Released elastase
(HLE) was complexed with al-proteinase inhibitor
(alPI) by addition of plasma (25%) and further
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incubated for 2 min. The samples were centrifuged
(10 min, 200 x g) and the HLE-alPI-complex
was measured by ELISA (Merck, Darmstadt,
Germany). Total HLE content of the PMN was
measured after lysis with cetyltrimethylammonium
bromide.
1
Preincubation experiments: Sixty ml of anticoagulated
blood were centrifuged and the plasma separated.
Ten ml of the plasma were activated and 10 ml
inactivated as described above. The blood was then
divided into three parts and each was treated in one
of the following ways: (1) PMN were directly
isolated from one part, (2) one part of the blood
was mixed with activated plasma (final concentra-
tion 10%) and incubated for 10 min at 37C, then
the PMN were isolated, (3) one part of the blood
was mixed with inactivated plasma (final concentra-
tion 10%) and treated as part 2.
Patient studies: Twenty-seven patients gave their
informed consent to participate in the study.
Haemodialysis (HD) was performed by an A 2008 C
(Fresenius, Bad Homburg, Germany) or an AK-10
(Gambro, Hechingen, Germany) volume controlled
equipment. As our dialyser we used cuprophane:
SMAD 125/140 (SMAD, Lyon, France), hemo-
phane: MO 450 (SMAD) and GFS 120/140 MCH
(Gambro, Lund, Sweden), and polysulfone: F6
(Fresenius).
EDTA blood was taken from the arterial line
before systemic heparinization prior to HD and 10,
30, 60, 120 and 180 min after the beginning of HD.
The blood was immediately centrifuged and the
plasma stored deep frozen until assessed for C5a by
ELISA.
Chemicals were if not otherwise stated by Sigma
Chemie, Deisenhofen, Germany.
Statistical analysis" Data are represented as the
mean-t-1 standard deviation (SD). Statistical
comparisons were performed by the paired
Student’s t-test.
Results
CSadesArg generation during diasis: Figure 1 shows the
kinetics of CSadesArg generation in the venous blood
samples during haemodialysis (HD). HD with
Cuprophane gives maximal levels of 55 #g
C5adesArg/1 after 30 min. HD with Hemophane Mo
450 or GF 120 results in lower values of maximal
8 #g CSadesArg/1 after 10 min of dialysis. Similar
results are obtained for HD with Polysulfone
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FIG. 1. Change of CSadesArg concentration as a function of dialysis time for different membrane materials.
62 Mediators of Inflammation. Vol 1992Neutrophilfunctions and C5adesArg
20-
15
2" 0 0 2.5 5 10
act. plasma [/o]
FIG. 2. Chemotaxis of human PMN stimulated with activated plasma.
Autologous plasma was activated and diluted in H BSS (final
concentration given on the abscissa). The cell migration was assayed for
90 min at 37 Data represent the mean-t-SD of five separate
experiments done in duplicate.
In vitro generation of CSadesArg" Generation of C5adesArg
by yeast activation of autologous plasma samples
results in a mean value of 1040 -+- 450/_zg C5adesarg/1
(n 8). In parallel inactivated plasma samples
contain 1.7 -t- 0.9/g C5adesarg/1 (n 8).
Stimulation of chemotaxis by activated plasma" Figure 2
shows the concentration dependent stimulation of
chemotaxis by the autologous plasma samples.
Maximal stimulation is achieved by 10% activated
plasma which corresponds to about 100
C5adesarg/l.
Stimulation of oxidative burst by activated plasma"
Direct effect of activated plasma. The superoxide
generation of PMN is already stimulated by 1% of
activated plasma corresponding to about 10g
C5a&sarg/1 to 2 nmol O-/10 min/106 PMN (Fig. 3).
Further addition of activated plasma up to 20%
(about 200 #g C5adesArg/1 enhances the superoxide
production to 13.7 nmol/10 rain/106 PMN.
Preincubation of PMN with activated plasma. To test
the effect of priming, blood was mixed with
activated or inactivated plasma (final concentration
10%) and incubated for 10 min at 37C, and then
the PMN were isolated. As a control, PMN from






FIG. 3. Superoxide anion generation of human PMN stimulated with
activated plasma. Autologous plasma was activated and incubated (in
the final concentration given on the abscissa) with PMN (106) and
cytochrome c (75 #M) for 10 min at 37C. Data represent the mean 4- SE
of three separate experiments done in duplicate.
The yield of PMN is reduced to 18% of the
control after incubation with activated plasma
(Table 1, p < 0.002). Incubation of the blood with
inactivated plasma also reduces the yield (55% of
control, not significant NS). If the superoxide
generation of the isolated PMN is tested without
the addition of a stimulus, the plasma preincubated
cells produce higher amounts of superoxide than
untreated cells (4.5 and 4.1 vs. 2.2 nmol O-/10
PMN/10 min, NS, Fig. 4). in contrast, generation
of superoxide is significantly reduced after PMN
stimulation of the C5adesarg preincubated cells: 9.5
nmol O-/10 min/10 PMN vs. 20.1 nmol of
control cells (p < 0.02) and 17.5 nmol of cells
incubated with inactivated plasma (p < 0.01). After
stimulation with activated plasma the C5adesArg
pretreated cells produce more superoxide than the
other groups: 9.3 nmol/10 min/10 PMN vs. 5.5
nmol of control cells (NS) and 5.1 nmol of
inactivated plasma incubated cells (p < 0.05).
Table 1. Yield of PMN after preincubation of the blood with
activated or inactivated plasma (final concentration 10%, 10
min, 37C) compared to untreated control blood
Preincubation PMN/20 ml blood Yield (%)
control 3.8 + 2.0 x 107 100
10% act. plasma 6.8 _+ 5.2 x 106 18
10% inact, plasma 2.1 _+ 1.6 x 107 55
Statistical significance by Student’s t-test: act.plasma vs. control
p < 0.002, act. vs. inact, plasma p < 0.05.










FIG. 4. Superoxide anion generation of human PMN after preincubation
with autologous plasma. PMN were directly isolated from blood (control)
or the blood was incubated (37C, 15 min) either with 10% activated
plasma (act. plasma) or with 10% inactivated plasma (inact. plasma)
before isolation. Superoxide anion generation was measured for 10 min
at 37C without addition of stimulus (0), after stimulation with PMA
(1 #g m1-1) (PMA) or with activated plasma (final concentration 20%)
(act. plasma). Data represent the mean-I-SD of eight separate
experiments done in duplicate. Statistical significance by Student’s t-test’
*p < 0.05, **p < 0.02, ***p < 0.01.
Preincubation of blood with lower concentra-
tions of activated plasma (final concentration 5%)
gives similar results as preincubation with in-
activated plasma (data not shown).
Stimulation of HLE release: Incubation of isolated
PMN with activated plasma results in no
stimulation of HLE release in the range of 1-20%
activated plasma.
Discussion
Human C5a is cleaved from the fifth component
of complement during activation and then rapidly
converted by a plasma enzyme to the CSadesArg
derivative.
11 The plasma levels of C5adesA in
healthy adults are normally below 0.2 #g 1-1.1
The measurement of C5a or C5adesArg is difficult
because of its short half-life. 13’4 Measurements







FIG. 5. HLE release of human PMN stimulated with activated plasma.
Autologous plasma was activated and incubated with PM N (4 x 106) in
the final concentration given on the abscissa for 15 min at 37C. Data
represent the mean _+ SD of six separate experiments done in duplicate.
during haemodialysis have to be made in venous
blood samples which come directly from the
dialyser, where C5a is supposed to be generated. ’15
We found maximal plasma levels of 55 #g
C5adesArg after 30 min of haemodialysis with
cuprophan membranes (Fig. 1) in accordance with
results of Knudsen, Bingel and Freyria
16<8
(maximal 35--61/g 1-1). The other membranes only
produced about 8 #g CSadesArg (Fig. 1).
For our in vitro experiments we generated
C5adesArg by yeast activation of the autologous
plasma samples, which resulted in 1040 4-450 #g
CSadesArg/1 on average, while the inactivated
samples only contained about 2/.tg 1-1. To test the
C5adesarg activity we performed chemotaxis experi-
ments (Fig. 2). Maximal stimulation was achieved
by 10% activated plasma corresponding to 60 nM
C5adesArg the same value as described by Yancey et
al.
19 and Chenoweth and Hugli.
2 The native C5a
fragment was about 20-fold more potent (ECs0 C5a
0.5 nM).
21
The stimulation of the oxidative burst with
activated plasma (Fig. 3) gave no maximum but was
increased in the whole range tested (final
concentration 1-20% activated plasma) as already
described by Goldstein.
22
So we found stimulation of chemotaxis and
oxidative burst by about 10% activated plasma,
which corresponded to 100 #g C5adesArg/1, the same
values found after haemodialysis with.cuprophan
membranes. To simulate the complement exposure
during dialysis, we preincubated blood with
10% activated plasma (final concentration 100 yg
C5a&sArg/1 blood) and as the control with 10%
inactivated plasma (final concentration 0.2yg
CSadesArg/1), and tested the subsequently isolated
PMN.
CSadesArg aggregates PMN23’24 and the aggregatedNeutrophilfunctions and C5aesArg
cells were separated by Ficoll centrifugation. So the
yield of PMN was rather reduced after incubation
with activated plasma (Table 1). The prestimulated
PMN produced less superoxide after further
stimulation with PMA than the control cells or the
cells that were preincubated with inactivated plasma
(Fig. 4). The extent of these effects differed from
one blood donor to the other, reflected by the large
standard deviations, but the ratio of the values was
always the same.
So the preincubation experiments imitate the in
vivo results, which also show leukopenia after
cuprophan dialysis25’26 and diminished superoxide
generation of the isolated PMN.4
It seems probable that after stimulation a
subpopulation of PMN with lower activity was
isolated,27’28 because priming of PMN with a
stimulus normally resulted in enhanced activity
towards a second stimulus.
29 However, if the
prestimulated PMN are further stimulated with
activated plasma, the superoxide generation is
enhanced in comparison to untreated cells (Fig. 4).
So the activated plasma seems to contain a factor
which compensates the cellular effect. These
apparently contradictory results are also produced
during dialysis, where the superoxide generation of
PMN in autologous plasma is enhanced at the same
time as the superoxide generation of isolated PMN
is reduced.3’31
Our preincubation experiments were performed
with high CSadesarg concentrations which corre-
spond to the values after cuprophane dialysis. And
they show similar results for PMN function as are
produced during cuprophane dialysis. Preincuba-
tion with lower C5aae,Arg concentrations (5%
activated plasma corresponding to a final concentra-
tion of about 50/g C5ades,rg/1) shows no effect. But
other membrane materials such as hemophane also
induce leukopenia and changes of PMN oxidative
burst although they only generate very small
amounts of C5adesArg. 4’16-18 So C5adesArg may be
responsible for the complement induced effects after
cuprophan dialysis but not for the effects after HD
with the other membranes. This is confirmed by
several other authors who find no correlation
between the extent of complement activation and
leukopenia.
2-35 Moreover complement activation
by cuprophane also depends on additional serum
factors which diflCer greatly between individuals.
6
The second cellular effect during dialysis, the
enzyme release,37’4 is not mimicked by activated
plasma. Incubation of isolated PMN with up to 20%
activated plasma results in no release of HLE (Fig.
5) Release of azurophil granules is only stimulated
after cytochalasin b preincubation
8 while only
specific granules are released by soluble stimuli.
9
So the HLE release of PMN during dialysis
4 can
not be explained by the activated plasma compo-
nents but additional stimulating effects of the
dialysis membrane have to be assumed.
CSadesarg generated during haemodialysis may
influence some of PMN functions e.g. the
oxidative burst. But for other functions e.g. the
enzyme release an additional influence of the
membrane material has to take effect.
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